GoldenGolden
Verona Pharma

Verona Pharma

Verona Pharma is a London-based biotechnology company working to discover new drugs for the treatment of chronic respiratory diseases.

Verona Pharma is a clinical‑stage biopharmaceutical company that focuses on developing and commercializing innovative prescription medicines. The company focuses on treating respiratory diseases with important and challenging medical needs, such as COPD, asthma and cystic fibrosis.

Verona Pharma is led by a team with deep industry experience and an indepth background in the discovery, research, development and commercialization of respiratory therapies. The company focuses on developing ensifentrine, which is potentially the first treatment of respiratory disease that combines bronchodilator and anti-inflammatory activity in one compound.

The company aims to enhance health and quality of life for several people that are affected by chronic respiratory diseases. Its development candidate, ensifentrine (RPL554), possesses the potential to offer relief for patients who are suffering from respiratory conditions like chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and asthma.

Timeline

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Nuance Pharma Limited
June 10, 2021
www.prnewswire.com:443
/PRNewswire/ -- Verona Pharma plc (Nasdaq: VRNA) ("Verona Pharma") and Nuance Pharma Limited ("Nuance Pharma"), today announce that the companies have entered...
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.